Premium
Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C ( CHC ) infected patients evaluated with controlled attenuation parameter ( CAP )
Author(s) -
Cardoso A. C.,
Perez R. M.,
FigueiredoMendes C.,
Carvalho Leite N.,
MoraesCoelho H. S.,
VillelaNogueira C. A.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12930
Subject(s) - steatosis , transient elastography , medicine , gastroenterology , fatty liver , liver steatosis , diabetes mellitus , hepatitis c , dyslipidemia , endocrinology , cirrhosis , obesity , liver fibrosis , disease
Summary A novel controlled attenuation parameter ( CAP ) using FibroScan ® has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography ( TE ) by FibroScan ® . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP < 222 dB /m = S0; CAP ≥ 222 dB /m and <233dB/m = S1; ≥233 dB /m < 290dB/m = S2 and >= 290 dB /m = S3. The prevalence of moderate/severe steatosis ( CAP ≥ S2) and the related independent factors were identified by a logistic regression analysis. A significance level of 5% was adopted. 1104 CHC patients, 85% genotype‐1 were included (mean age 55 ± 11 years; 46% male, mean BMI 25 ± 4 Kg/m 2 ). Systemic arterial hypertension and type 2 diabetes mellitus prevalences were 39% and 17%, respectively. Liver stiffness measurement ≥ 9.5 kP a was observed in 39% of patients and steatosis was identified in 50% (S1 = 7%, S2 = 28% and S3 = 15%). The variables independently associated with moderate/severe steatosis were: male gender ( OR =1.35; P = .037; 95% CI :1.01‐1.81); systemic arterial hypertension ( OR =1.57; P = .002; 95% CI :1.17‐2.10) and BMI ( OR =1.17; P < .01;95% CI :1.12‐1.22). In conclusion, when CAP was adopted as a tool to detect steatosis, genotype 1 CHC patients presented a high prevalence of moderate/advanced steatosis. In these patients, liver steatosis was associated mostly to metabolic factors (arterial hypertension and high BMI).